This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

iTeos Therapeutics 향후 성장

Future 기준 점검 0/6

iTeos Therapeutics은 연간 수입과 매출이 각각 8.9%와 63.4% 증가할 것으로 예상되고 EPS는 연간 15.4%만큼 증가할 것으로 예상됩니다.

핵심 정보

8.9%

이익 성장률

15.41%

EPS 성장률

Biotechs 이익 성장	22.1%
매출 성장률	63.4%
향후 자기자본이익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	06 Aug 2025

최근 향후 성장 업데이트

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Nov 15

Recent updates

iTeos Therapeutics: Decimated By Collateral Events, Good Chances Of Success Nevertheless

Feb 27

iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024

Dec 18

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Nov 15

iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT

Sep 15

Is iTeos Therapeutics (NASDAQ:ITOS) In A Good Position To Deliver On Growth Plans?

Aug 11

iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism

Jul 09

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Looks Inexpensive But Perhaps Not Attractive Enough

Jan 25

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

Jan 10

Industry Analysts Just Upgraded Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Revenue Forecasts By 16%

May 13

Investors Give iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares A 25% Hiding

Mar 21

The Consensus EPS Estimates For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Just Fell Dramatically

Aug 12

iTeos Therapeutics GAAP EPS of $0.16 misses by $1.04

Aug 10

iTeos Therapeutics: Too Many Unknowns

Jul 27

News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts

May 11

Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic

Nov 25

이익 및 매출 성장 예측

NasdaqGM:ITOS - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2027	N/A	-136	N/A	-157	4
12/31/2026	N/A	-96	N/A	-152	5
12/31/2025	-6	-188	N/A	-143	5
6/30/2025	N/A	-202	-109	-108	N/A
3/31/2025	35	-131	-100	-100	N/A
12/31/2024	35	-134	-100	-98	N/A
9/30/2024	35	-121	-120	-117	N/A
6/30/2024	35	-108	-118	-114	N/A
3/31/2024	N/A	-135	-113	-110	N/A
12/31/2023	13	-113	-107	-104	N/A
9/30/2023	67	-62	-119	-117	N/A
6/30/2023	86	-28	-114	-113	N/A
3/31/2023	128	12	-115	-114	N/A
12/31/2022	268	97	-112	-111	N/A
9/30/2022	454	261	-144	-143	N/A
6/30/2022	539	330	490	492	N/A
3/31/2022	497	298	503	504	N/A
12/31/2021	345	215	512	513	N/A
9/30/2021	104	15	565	566	N/A
6/30/2021	N/A	-67	-49	-49	N/A
3/31/2021	N/A	-50	-41	-40	N/A
12/31/2020	N/A	-43	-26	-25	N/A
9/30/2020	N/A	-35	-27	-27	N/A
6/30/2020	N/A	-31	-22	-22	N/A
3/31/2020	N/A	-28	-18	-18	N/A
12/31/2019	N/A	-27	-24	-23	N/A

애널리스트 향후 성장 전망

수입 대 저축률: ITOS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: ITOS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: ITOS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: ITOS 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 매출: ITOS 은(는) 내년에 수익이 없을 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: ITOS의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/08/30 13:37
종가	2025/08/28 00:00
수익	2025/06/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 우리의 Github 페이지에서 확인하실 수 있으며, 보고서를 활용하는 방법에 대한 가이드와 유튜브 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

iTeos Therapeutics, Inc.는 3명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Michael Ulz	Baird
Derek Archila	Wells Fargo Securities, LLC
Eva Fortea-Verdejo	Wells Fargo Securities, LLC

This company has been acquired

iTeos Therapeutics 향후 성장

Future 기준 점검 0/6

핵심 정보

최근 향후 성장 업데이트

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Price target decreased by 11% to US$35.75

Consensus revenue estimates increase by 46%

Price target decreased by 8.9% to US$40.27

Consensus revenue estimates fall by 23%

Price target decreased to US$46.20

Recent updates

iTeos Therapeutics, Inc.(NasdaqGM:ITOS) dropped from NASDAQ Composite Index

Concentra Biosciences, LLC completed the acquisition of iTeos Therapeutics, Inc. (NasdaqGM:ITOS) from a group of shareholders.

Concentra Biosciences, LLC agreed to acquire iTeos Therapeutics, Inc. (NasdaqGM:ITOS) from a group of shareholders for approximately $470 million in a tender offer transaction.

iTeos Therapeutics, Inc. Announces Resignation of Tim Van Hauwermeiren from the Board of Directors, Effective from June 1, 2025

iTeos Therapeutics, Inc. Announces Its Intention to Wind Down Operations

iTeos Therapeutics, Inc. Reports Topline Interim Results from Galaxies Lung-201 Study of Belrestotug + Dostarlimab in First-Line, Pd-L1 High Non-Small Cell Lung Cancer Patients

iTeos Therapeutics, Inc., Annual General Meeting, Jun 17, 2025

iTeos Therapeutics, Inc. Completes Enrollment of Second Dose Cohort of EOS-984 + Pembrolizumab Combination in Ongoing Phase 1 Trial

iTeos Therapeutics: Decimated By Collateral Events, Good Chances Of Success Nevertheless

iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024

iTeos Therapeutics, Inc. Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT

Is iTeos Therapeutics (NASDAQ:ITOS) In A Good Position To Deliver On Growth Plans?

iTeos Therapeutics, Inc. Appoints David Feltquate as Chief Medical Officer

iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism

iTeos Therapeutics, Inc.(NasdaqGM:ITOS) dropped from Russell 2000 Value-Defensive Index

iTeos Therapeutics, Inc. and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

New minor risk - Shareholder dilution

iTeos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $119.994271 million.

New major risk - Revenue size

Insufficient new directors

iTeos Therapeutics, Inc., Annual General Meeting, Jun 11, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

iTeos Therapeutics, Inc. Appoints Jill DeSimone to its Board of Directors, Effective March 7, 2024

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Looks Inexpensive But Perhaps Not Attractive Enough

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

Iteos Therapeutics, Inc. Announces Business Updates and Strategic Priorities for 2024

Iteos Therapeutics, Inc. Announces Board Changes

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.90 loss per share (vs US$0.028 profit in 3Q 2022)

New minor risk - Share price stability

Price target decreased by 11% to US$35.75

Second quarter 2023 earnings released: US$0.96 loss per share (vs US$0.16 profit in 2Q 2022)

Investor sentiment improves as stock rises 18%

Consensus revenue estimates increase by 46%

Industry Analysts Just Upgraded Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Revenue Forecasts By 16%

Price target decreased by 8.9% to US$40.27

Chief Operating Officer exercised options to buy US$531k worth of stock.

Investor sentiment deteriorates as stock falls 17%

Investors Give iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares A 25% Hiding

High number of new directors

iTeos Therapeutics, Inc. Announces Resignation of Matthew Roden from the Board

Investor sentiment improves as stock rises 17%

Investor sentiment deteriorated over the past week

High number of new directors

Consensus revenue estimates fall by 23%

The Consensus EPS Estimates For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Just Fell Dramatically

iTeos Therapeutics GAAP EPS of $0.16 misses by $1.04

iTeos Therapeutics: Too Many Unknowns

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Independent Chairman of the Board notifies of intention to sell stock

Investor sentiment improved over the past week

High number of new directors

Price target decreased to US$46.20

Investor sentiment deteriorated over the past week

News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts

Consensus revenue estimates increase by 30%

Price target increased to US$50.20

President notifies of intention to sell stock

iTeos Therapeutics, Inc., Annual General Meeting, Jun 09, 2022

President exercised options and sold US$318k worth of stock

Price target increased to US$50.20

Consensus revenue estimates fall by 29%

Chief Medical Officer exercised options and sold US$111k worth of stock

Chief Scientific Officer exercised options and sold US$325k worth of stock